We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-Based Regimens.
- Authors
Kourea, Helen P.; Dimitrakopoulos, Foteinos-Ioannis; Koliou, Georgia-Angeliki; Batistatou, Anna; Papadopoulou, Kyriaki; Bobos, Mattheos; Asimaki-Vlachopoulou, Anthoula; Chrisafi, Sofia; Pavlakis, Kitty; Chatzopoulos, Kyriakos; Galani, Eleni; Pentheroudakis, George; Pectasides, Dimitrios; Bafaloukos, Dimitrios; Res, Eleni; Papakostas, Pavlos; Koutras, Angelos; Kotoula, Vassiliki; Fountzilas, George
- Abstract
Purpose Angiogenesis is a crucial phenomenon in the development and progression of breast cancer (BC), but the clinical significance of angiogenesis-related proteins in metastatic BC remains unknown. This study investigates the prognostic value of vascular endothelial growth factor receptors 1, 2, 3 (VEGFR1, VEGFR2, VEGFR3) as well as vascular endothelial growth factors A and C (VEGFA and VEGFC) in metastatic BC patients treated with trastuzumab-based regimens. Materials and Methods Two hundred female patients were included. Protein and mRNA expression of the studied angiogenesis-related factors were evaluated by immunohistochemistry and quantitative polymerase chain reaction, respectively. Results High expression of VEGFA, VEGFC, VEGFR1, VEGFR2, and VEGFR3 in the tumor cells was observed in 43.5%, 24.2%, 36%, 29.5%, and 43%, respectively. Stromal elements expressed high levels of VEGFA, VEGFC, VEGFR1, VEGFR2, and VEGFR3 in 78.9%, 93.3%, 90.7%, 90.2%, and 74.8% of tumors with available data. High tumor cell expression of VEGFR1 was a favorable prognosticator for survival among patients with human epidermal growth factor receptor 2 (HER2)-positive tumors (hazard ratio [HR], 0.55; p=0.013). A trend towards longer progression-free survival was detected univariately for patients with HER2-negative tumors and high expression of VEGFR2 (HR, 0.60; p=0.059). Conclusion VEGFR1 and VEGFR2 seem to have significant prognostic value in BC patients with metastatic disease treated with trastuzumab-based regimens.
- Subjects
METASTATIC breast cancer; VASCULAR endothelial growth factor receptors; VASCULAR endothelial growth factors; EPIDERMAL growth factor receptors; PROGNOSIS
- Publication
Cancer Research & Treatment, 2022, Vol 54, Issue 4, p1053
- ISSN
1598-2998
- Publication type
Article
- DOI
10.4143/crt.2021.748